Review




Structured Review

GenomeDx Inc genome-wide microarray gene expression data
Genome Wide Microarray Gene Expression Data, supplied by GenomeDx Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/genome-wide+microarray+gene+expression+data/genome+wide+microarray+gene+expression+data/pm34795264-102-21-33
Average 90 stars, based on 1 article reviews
genome-wide microarray gene expression data - by Bioz Stars, 2026-10
90/100 stars

Images

Related Articles

Genome Wide:

Article Title: G3BP1 inhibits Cul3 SPOP to amplify AR signaling and promote prostate cancer
Article Snippet: We evaluated the probability of metastasis-free survival of primary 1626 PCa patients stratified based on low or high G3BP1 group using genome-wide microarray gene expression data from a clinically available prognostic assay (Decipher; GenomeDx Biosciences, Vancouver, BC, Canada) .

Article Title: G3BP1 inhibits Cul3 SPOP to amplify AR signaling and promote prostate cancer.
Article Snippet: We evaluated the probability of metastasis-free survival of primary 1626 PCa patients stratified based on low or high G3BP1 group using genome-wide microarray gene expression data from a clinically available prognostic assay (Decipher; GenomeDx Biosciences, Vancouver, BC, Canada)37.

Article Title: Impact of the SPOP Mutant Subtype on the Interpretation of Clinical Parameters in Prostate Cancer
Article Snippet: We used the SCaPT model to predict the molecular subclass from a retrospective cohort that included 1,626 patient samples and a prospective cohort that included 6,532 samples using genome-wide microarray gene expression data from a clinically available prognostic assay (Decipher; GenomeDx Biosciences, Vancouver, BC, Canada), and we explored the clinicopathologic and prognostic associations of key molecular subclasses of prostate cancer.

Microarray:

Article Title: G3BP1 inhibits Cul3 SPOP to amplify AR signaling and promote prostate cancer
Article Snippet: We evaluated the probability of metastasis-free survival of primary 1626 PCa patients stratified based on low or high G3BP1 group using genome-wide microarray gene expression data from a clinically available prognostic assay (Decipher; GenomeDx Biosciences, Vancouver, BC, Canada) .

Article Title: G3BP1 inhibits Cul3 SPOP to amplify AR signaling and promote prostate cancer.
Article Snippet: We evaluated the probability of metastasis-free survival of primary 1626 PCa patients stratified based on low or high G3BP1 group using genome-wide microarray gene expression data from a clinically available prognostic assay (Decipher; GenomeDx Biosciences, Vancouver, BC, Canada)37.

Article Title: Impact of the SPOP Mutant Subtype on the Interpretation of Clinical Parameters in Prostate Cancer
Article Snippet: We used the SCaPT model to predict the molecular subclass from a retrospective cohort that included 1,626 patient samples and a prospective cohort that included 6,532 samples using genome-wide microarray gene expression data from a clinically available prognostic assay (Decipher; GenomeDx Biosciences, Vancouver, BC, Canada), and we explored the clinicopathologic and prognostic associations of key molecular subclasses of prostate cancer.

Gene Expression:

Article Title: G3BP1 inhibits Cul3 SPOP to amplify AR signaling and promote prostate cancer
Article Snippet: We evaluated the probability of metastasis-free survival of primary 1626 PCa patients stratified based on low or high G3BP1 group using genome-wide microarray gene expression data from a clinically available prognostic assay (Decipher; GenomeDx Biosciences, Vancouver, BC, Canada) .

Article Title: G3BP1 inhibits Cul3 SPOP to amplify AR signaling and promote prostate cancer.
Article Snippet: We evaluated the probability of metastasis-free survival of primary 1626 PCa patients stratified based on low or high G3BP1 group using genome-wide microarray gene expression data from a clinically available prognostic assay (Decipher; GenomeDx Biosciences, Vancouver, BC, Canada)37.

Article Title: Impact of the SPOP Mutant Subtype on the Interpretation of Clinical Parameters in Prostate Cancer
Article Snippet: We used the SCaPT model to predict the molecular subclass from a retrospective cohort that included 1,626 patient samples and a prospective cohort that included 6,532 samples using genome-wide microarray gene expression data from a clinically available prognostic assay (Decipher; GenomeDx Biosciences, Vancouver, BC, Canada), and we explored the clinicopathologic and prognostic associations of key molecular subclasses of prostate cancer.



Similar Products

90
GenomeDx Inc genome-wide microarray gene expression data
Genome Wide Microarray Gene Expression Data, supplied by GenomeDx Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/genome-wide+microarray+gene+expression+data/genome+wide+microarray+gene+expression+data/pm34795264-102-21-33
Average 90 stars, based on 1 article reviews
genome-wide microarray gene expression data - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
Illumina Inc genome-wide gene expression microarray data
Genome Wide Gene Expression Microarray Data, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/genome-wide+microarray+gene+expression+data/whole+genome+expression+arrays/10__1172_slash_jci82661-149-2-3
Average 90 stars, based on 1 article reviews
genome-wide gene expression microarray data - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

Image Search Results